Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196264 | 0.91 | GPR52 (0.73) | GPR52PTGER4CTSALMNAKDM4E | |
| SCHEMBL3219790 | 0.86 | GPR52 (0.67) | GPR52PTGER4LMNASCD5 | |
| SCHEMBL3219255 | 0.86 | GPR52 (0.66) | GPR52PTGER4 | |
| SCHEMBL3206470 | 0.85 | GPR52 (0.81) | GPR52PTGER4 | |
| SCHEMBL1850158 | 0.84 | GPR52 (0.56) | GPR52PTGER4CTSALMNATP53 | |
| SCHEMBL7956119 | 0.83 | GPR52 (0.62) | GPR52PTGER4CTSALMNATP53 | |
| SCHEMBL3204342 | 0.83 | GPR52 (0.68) | GPR52PTGER4KDM4E | |
| SCHEMBL1856279 | 0.82 | GPR52 (0.77) | GPR52PTGER4 | |
| SCHEMBL7961131 | 0.77 | GPR52 (0.80) | GPR52PTGER4 | |
| SCHEMBL3210140 | 0.77 | GPR52 (0.80) | GPR52PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885PTGER4 888/4885CTSA 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.